New cancer clinical trial: Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer

Published on: June 22, 2018 at 12:00PM
Conditions:   Stage III Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer;   Estrogen Receptor-positive;   HER2/Neu Negative
Interventions:   Drug: Atezolizumab;   Drug: Cobimetinib;   Drug: Idasanutlin
Sponsors:   Vanderbilt-Ingram Cancer Center;   Genentech, Inc.;   Stand Up To Cancer
Not yet recruiting
https://ift.tt/2lBaXcI